Update: Late stage springing forward
Mesoblast’s late-stage product pipeline is burgeoning. We expect a regulatory decision for its first product, MSC-100-IV in acute graft vs host disease (aGvHD) in Japan in mid-2015 following its filing last October, which would serve as critical confirmation of the company’s proprietary mesenchymal stem cell (MSC) technology. Two further products, MPC-150 in CHF and MPC-100-IV have entered pivotal Phase III trials over the past year. We increase our valuation of the company to A$3.41bn from A$3.16bn or A$10.51 per basic share from A$9.51 per basic share, representing significant upside to the current share price.Mesoblast is engaged in the development of regenerative medicine products. Co. has leveraged its proprietary technology platform, based on specialized cells known as mesenchymal lineage adult stem cells ("MLCs"), to establish a portfolio of late-stage product candidates. Co.'s allogeneic, "off the shelf" product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology and hematologic conditions. Each MLC-derived product candidate has technical characteristics, target indications, reimbursement strategy, commercialization potential, and partnering opportunities.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.